摘要
目的比较(国产)喹硫平和利培酮治疗慢性男性精神分裂症的临床疗效与不良反应。方法将符合入组标准的60例慢性男性精神分裂症住院患者随机分为喹硫平组30例和利培酮组30例,分别给予喹硫平和利培酮治疗6周,采用简明精神病评定量表(BPRS),副反应量表(TESS)分别评定疗效和不良反应。用简易智能状态检查量表(MMSE)测评对认知功能的影响。结果治疗结束时,两组BPRS评分较入组时均明显下降(P<0.01);两组MMSE评分明显增加(P<0.05)。两组之间无显著性差异(P>0.05),但喹硫平组较利培酮组不良反应少而轻。结论 (国产)喹硫平治疗慢性男性精神分裂症安全性高,依从性好,是一种有效且安全的新型抗精神病药物。
Objective To compare the efficacy and safety between（Domestic）quetiapine and risperidone in the treatment of chronic male schizophrenia.Methods 60 patients with chronic male schizophrenia were randomly divided into quetiapine group and risperidone group,and treated with quetiapine and risperidone respectively for 6 weeks.Brief Psychiatric Rating Scale（BPRS）was used to assess the clinical efficacy,and Treatment Emergent Symptom Scale（TESS）was used to assess adverse reactions.cognitive function was assessed by Mini-Mental State Examination （MMSE）.Results At the end of treatment,two group BPRS scores,were significantly reduced（P〈0.01）;two group MMSE scores,were significantly increased（P〈0.05）.There is no significant difference in the two groups（P〉0.05）.but contrast risperidone,quetiapine has less and slight side reactions.Conclusion（Domestic）quetiapine is an effective and safe drug,as new atypical antipsychotic to treat Chronic male schizophrenia.This therapy is efficient and high safe.
出处
《当代医学》
2010年第15期130-131,共2页
Contemporary Medicine
